Dianthus Therapeutics, Inc. (DNTH)
Develops antibody drugs to treat severe autoimmune diseases by targeting specific immune system proteins
$102.02-0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+395.5%
The outlook
DNTH is trading near its 52-week highs, well above its short and long-term moving averages, reflecting strong recent momentum. Analyst consensus suggests the average price target sits roughly 26% above the current price. The overall sentiment leans bullish based on current technicals and analyst positioning.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range93% of the way from its 52-week low to high
Price targetAvg target +26% vs current price
Analyst price target
~12-month · 12 analysts$128.58average target+26.0% vs now
Now $102.02
Low $105.00High $200.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$5.58B
52-wk high
$107.99
52-wk low
$18.08
50-day avg
$90.97
200-day avg
$65.21
Trailing P/E
—